Article Text

Download PDFPDF
Endosaccular flow disruption: where are we now?
  1. Pervinder Bhogal1,
  2. Sundip Udani2,
  3. Christophe Cognard3,
  4. Michel Piotin4,
  5. Patrick Brouwer5,
  6. Nader-Antoine Sourour6,
  7. Tommy Andersson5,
  8. Levansri Makalanda1,
  9. Ken Wong1,
  10. David Fiorella7,8,
  11. Adam S Arthur9,
  12. Leonard LL Yeo10,
  13. Michael Soderman5,11,
  14. Hans Henkes12,
  15. Laurent Pierot13
  1. 1 Department of Interventional Neuroradiology, The Royal London Hospital, London, UK
  2. 2 Department of Neuroradiology, The Royal London Hospital, London, UK
  3. 3 Diagnostic and Therapeutic Neuroradiology, Hôpital Purpan, Toulouse, France
  4. 4 Department of Interventional Neuroradiology, Fondation Rothschild Hospital, Paris, France
  5. 5 Neuroradiology, Karolinska Universitetssjukhuset, Stockholm, Sweden
  6. 6 Neuroradiology, Pitié-Salpêtrière Hospital, Paris, France
  7. 7 Department of Neurosurgery, Stony Brook University, Stony Brook, New York, USA
  8. 8 SUNY SB, New York City, New York, USA
  9. 9 UT Dept Neurosurgery/Semmes-Murphey Clinic, Memphis, Tennessee, USA
  10. 10 NUHS, Singapore, Singapore
  11. 11 Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
  12. 12 Klinik für Neuroradiologie, Klinikum Stuttgart, Stuttgart, Germany
  13. 13 Radiology, University Hospital Reims, Reims, France
  1. Correspondence to Dr Pervinder Bhogal, Department of Interventional Neuroradiology, The Royal London Hospital, London, UK; bhogalweb{at}


Endosaccular flow disruption is an innovative method of treating wide-necked complex aneurysms. Currently four types of devices have obtained the CE mark for use within Europe. These are the Woven EndoBridge device (WEB), the Luna Aneurysm Embolization System, the Medina Embolic Device (Medtronic), and the Contour Neurovascular System. The aim of this article is to provide an overview of these devices and to summarize the evidence in the literature pertaining to the treatment of intracranial aneurysms with them.

  • flow disruption
  • WEB
  • MED
  • contour

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors PBh: manuscript preparation, review, editing, guarantor. SU: manuscript preparation, review, editing. CC: review, editing, contribution of cases. MP: review, editing. N-AS: review, editing. PBr: review, editing. TA: review, editing. LM: review, editing. KW: review, editing. DF: review, editing. ASA: review, editing. MS: review, editing, case contribution. HH: review, editing. LP: review, editing. LLLY - editing, review of manuscript, data collection.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests PBh: consultant for phenox. CC: consultant for Stryker, Medtronic, Cerenovus and Microvention. MP: consultant for Medtronic, Stryker, MicroVention, Balt, Penumbra, Base Camp Vascular (share holder). N-AS: investor in Medina. PBr: consultant for Cerenovus. TA: consultant for Ablynx, Amnis Therapeutics, Anaconda, Cerenovus–Neuravi, Medtronic-Covidien, Rapid Medical. DF: consultant for Medtronic, Microvention, Penumbra, Balt, Cerenovus, Stryker; research support: Siemens, Microvention, Penumbra, Cerenovus; stockholder: Marblehead, Neurogami, Vascular Simulations; board member: Vascular Simulations. ASA: consultant for Balt, Johnson and Johnson, Leica, Medtronic, Microvention, Penumbra, Scientia, Siemens, Stryker; shareholder in Bendit, Cerebrotech, Endostream, Magneto, Marblehead, Neurogami, Serenity, Synchron, Triad Medical, Vascular Simulations. MS: consultant for Cerenovus and Archer Research. HH: co-founder and shareholder for phenox GmbH and femtos GmbH. LP: consultant for Balt, Cerus Endovascular, MicroVention, Phenox, Vesalio, Penumbra.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Patient consent for publication Not required.